Impact of new therapeutics for hepatitis C virus infection in incarcerated populations

scientific article published on February 2013

Impact of new therapeutics for hepatitis C virus infection in incarcerated populations is …
instance of (P31):
scholarly articleQ13442814

External links are
P932PMC publication ID3875217
P698PubMed publication ID23596276

P50authorBenjamin LinasQ56655086
P2093author name stringArthur Y Kim
Barbara H McGovern
Warren J Ferguson
Robert Trestman
Amy Jo Harzke
Lara B Strick
Arthur Brewer
Anne S Spaulding
Jean C Sullivan
Jeff Dickert
P2860cites workOutcomes of treatment for hepatitis C virus infection by primary care providersQ24601722
Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity programQ24676385
Prevention and control of infections with hepatitis viruses in correctional settingsQ26151271
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionQ27860901
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialQ27860949
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseQ29547886
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Diagnosis, management, and treatment of hepatitis CQ29620656
HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunityQ30882906
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settingsQ33834958
Preliminary study of two antiviral agents for hepatitis C genotype 1.Q34030288
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.Q34294185
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemicQ34554572
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regressionQ34787367
A framework for management of hepatitis C in prisonsQ36479796
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysisQ36652084
The economics of hepatitis C virusQ36681596
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsQ36843554
Screening for HCV infection in jailsQ36983871
Limited uptake of hepatitis C treatment among injection drug usersQ37238205
Public health impact of antiviral therapy for hepatitis C in the United StatesQ39939298
End-stage liver disease in a state prison populationQ43039878
Treatment of chronic hepatitis C in a state correctional facilityQ43042164
Surprisingly small effect of antiviral treatment in patients with hepatitis C.Q43889137
Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.Q45366817
Hepatitis C in state correctional facilitiesQ46143259
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.Q50552857
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.Q53118691
The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997Q78447515
Diversity of release patterns for jail detainees: implications for public health interventionsQ82265286
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectHepatitis C virusQ708693
hepatitis CQ154869
P304page(s)27-35
P577publication date2013-02-01
P1433published inTopics in antiviral medicineQ26841872
P1476titleImpact of new therapeutics for hepatitis C virus infection in incarcerated populations
P478volume21

Reverse relations

cites work (P2860)
Q35174428"Seek, test, treat and retain" for hepatitis C in the United States criminal justice system.
Q35915999A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System
Q56654943A Guide to the Economics of Hepatitis C Virus Cure in 2017
Q53572231A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991.
Q55154717CROI 2018: Highlights of Viral Hepatitis.
Q30248944Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis.
Q35543361Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system
Q64124224Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons
Q51846147Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings.
Q34941459HCV infected prisoners: should they be still considered a difficult to treat population?
Q54593526Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails.
Q59350307Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016
Q26785981Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment
Q36862066Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
Q30377895Public health and international drug policy.
Q35037688Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis
Q33710740The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients
Q35210085The need for higher standards in correctional healthcare to improve public health
Q40039247Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health

Search more.